Apr. 12, 2011 Estrogen treatment for osteoporosis has often been associated with serious side effects. Researchers at the Sahlgrenska Academy, University of Gothenburg, Sweden, have now, in mice, found a way of utilizing the positive effects of estrogen in mice so that only the skeleton is acted on, current research at the Academy shows.
The study is presented in the Proceedings of the National Academy of Sciences.
Many women are affected by osteoporosis after the menopause, when the body's production of estrogen decreases. Estrogen is the hormone that principally strengthens the bone mass in women, and it is also of significance for the skeleton in men. Treatment of osteoporosis with estrogens is, however, associated with serious side effects such as breast cancer and blood clots. In order to develop an estrogen treatment that utilizes the favorable effects of the estrogen but not its side effects, the researchers have analyzed which parts of the estrogen receptor is most important in enabling estrogen to act on bone tissue and other tissues.
Estrogen has recipient molecules known as estrogen receptors, which cause the body to respond to estrogen.
"This is the first study to analyze the significance of different parts of a particular type of estrogen receptor through studies in mice. It enables us to differentiate the favorable effects of estrogen in bone tissue from the adverse effects in other tissues," says Anna Börjesson, a PhD student at the Centre for Bone and Arthritis Research at the Sahlgrenska Academy.
This knowledge improves the prospects of being able to develop new, safer estrogen treatments in the future.
"The development of special estrogens that are tailored to bone and only affect a particular part of this type of estrogen receptor may lead to a more targeted and effective treatment for osteoporosis with minimal side effects," Professor Claes Ohlsson explains.
Other social bookmarking and sharing tools:
Note: Materials may be edited for content and length. For further information, please contact the source cited above.
- A. E. Borjesson, S. H. Windahl, M. K. Lagerquist, C. Engdahl, B. Frenkel, S. Moverare-Skrtic, K. Sjogren, J. M. Kindblom, A. Stubelius, U. Islander, M. C. Antal, A. Krust, P. Chambon, C. Ohlsson. Roles of transactivating functions 1 and 2 of estrogen receptor-α in bone. Proceedings of the National Academy of Sciences, 2011; DOI: 10.1073/pnas.1100454108
Note: If no author is given, the source is cited instead.